James Hardie Industries plc. Ordinary Shares vs Novavax Inc — how do they compare? James Hardie Industries plc. Ordinary Shares trades at $25.07 (market cap $14.60B), while Novavax Inc trades at $12.61 (market cap $1.82B). The key difference: James Hardie Industries plc. Ordinary Shares is far larger — about 8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, James Hardie Industries plc. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold James Hardie Industries plc. Ordinary Shares for 0 Days and Novavax Inc for 59 Days on average.
| JHX | NVAX | |
|---|---|---|
Market Cap | $14.60B | $1.82B |
Volume | 7,262,924 | 6,198,505 |
Sector | Basic Materials | Health |
52-Week High | $31.08 | $12.56 |
52-Week Low | $16.69 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $18.83B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
James Hardie manufactures fiber cement products for residential and commercial construction. Its portfolio includes exterior siding, interior boards, and other building materials.
Read more on JHX →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →